Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1-3 fibrosis.

Yuya Seko, Taichiro Nishikawa, Atsushi Umemura, Kanji Yamaguchi, Michihisa Moriguchi, Kohichiroh Yasui, Mayumi Kimura, Hiroaki Iijima, Toshio Hashimoto, Yoshio Sumida, Takeshi Okanoue, Yoshito Itoh

Diabetes, metabolic syndrome and obesity : targets and therapy

2018/11

10.2147/DMSO.S184767